Dosimetry in Peptide radionuclide receptor therapy: a review.
暂无分享,去创建一个
Giampiero Tosi | Giovanni Paganelli | Marta Cremonesi | Mahila Ferrari | Lisa Bodei | M. Ferrari | M. Cremonesi | G. Paganelli | L. Bodei | G. Tosi
[1] K. Endo,et al. Radiation dosimetry for indium-111-pentetreotide. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] M. Cremonesi,et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[3] George Sgouros,et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] E P Krenning,et al. Peptide receptor imaging and therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] Ryan Park,et al. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] Xiaowei Liu,et al. 3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. , 2003, Cancer biotherapy & radiopharmaceuticals.
[7] George Sgouros,et al. Dosimetry of internal emitters. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] J. Eary,et al. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] T. Visser,et al. Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy , 1998, International journal of cancer.
[10] David M. Goldenberg,et al. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations , 1998, European Journal of Nuclear Medicine.
[11] M. Konijnenberg,et al. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? , 2003, Cancer biotherapy & radiopharmaceuticals.
[12] A. Safavy,et al. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate. , 2004, Cancer biotherapy & radiopharmaceuticals.
[13] Ludwig G Strauss,et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. , 2005, Journal of Nuclear Medicine.
[14] E. Nitzsche,et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] B. Wessels,et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] R Laforest,et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] S. Adelstein,et al. Radiobiologic principles in radionuclide therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] E. Krenning,et al. Candidates for peptide receptor radiotherapy today and in the future. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] Raffaella Barone,et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] R. Valkema,et al. Radiolabelled peptides for tumour therapy: current status and future directions , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[21] E. Krenning,et al. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients , 2001, European Journal of Nuclear Medicine.
[22] R. Valkema,et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[23] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.
[24] Eva Forssell-Aronsson,et al. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] P. Bartenstein,et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[26] H. V. van Boven,et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] F. Forrer,et al. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[28] T. Visser,et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] R. Dale,et al. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. , 2004, Cancer biotherapy & radiopharmaceuticals.
[30] R. Moncayo,et al. 111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial , 2002 .
[31] H. Herzog,et al. PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[32] H. Herzog,et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide , 2001, European Journal of Nuclear Medicine.
[33] M. Cremonesi,et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[34] B. Bernard,et al. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] R. Moncayo,et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. , 2002, Seminars in nuclear medicine.
[36] M. Béhé,et al. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. , 2002, Cancer biotherapy & radiopharmaceuticals.
[37] L. Travaini,et al. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-Octreotide: Implications for internal radiotherapy with 90Y-DOTATOC , 2000 .
[38] S. Walrand,et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86 , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[39] Marion de Jong,et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] J. Siegel,et al. Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters. , 2002, Cancer biotherapy & radiopharmaceuticals.
[41] R. Motte. Society of Nuclear Medicine , 1981 .
[42] E P Krenning,et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. , 2001, European journal of nuclear medicine.
[43] K. Eckerman,et al. Evolution and status of bone and marrow dose models. , 2002, Cancer biotherapy & radiopharmaceuticals.
[44] C. Van de Wiele,et al. Renal Toxicity after Radionuclide Therapy , 2004, Radiation research.
[45] Larson,et al. Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[46] R. Valkema,et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.
[47] G Sgouros,et al. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[48] R. Pedley,et al. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture. , 2004, Cancer biotherapy & radiopharmaceuticals.
[49] Raffaella Barone,et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[50] M. Cremonesi,et al. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[51] U. Haberkorn,et al. (68)Ga-labeled peptides in tumor imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[52] J. O’Donoghue. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. , 2004, Cancer biotherapy & radiopharmaceuticals.
[53] Michael G Stabin,et al. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[54] L. Kvols,et al. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[55] E. Krenning,et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] R. Valkema,et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] M. Schwaiger,et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[58] E. Krenning,et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] F. Orsi,et al. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC , 1999, European Journal of Nuclear Medicine.